OMER on Nasdaq
OMEROS CORP
American pharmaceutical preparations company based in Seattle. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Bicycle Therapeutics (United Kingdom), AbCellera Biologics Inc. or ASSEMBLY BIOSCIENCES, INC., or pick any stock.
- TickerOMER on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersSeattle, United States2
- Incorporated inWA3
- Business address201 Elliott Avenue West, Seattle, Wa 981193
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formProfit Corporation2
- LEI549300CJWLXX2MXVVV712
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O REGISTERED AGENT SOLUTIONS, INC., 98501 Tumwater, United States2
- Registered withCorporations Division (Office of the Secretary of State), 601 553 2682
See how the biggest companies compare on our leaderboards
Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2020
Where the money goes
Where each dollar of revenue went, fiscal 2020
- Cost of revenue1¢$902.0K
- Research and development68¢$107.6M
- Interest17¢$26.8M
- Income tax15¢$23.3M
Out of $73.8M in revenue.65 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $81.3M | $119.5M | $114.9M |
| Selling, general and administrative | $41.5M | $47.4M | $49.7M |
| Total costs and expenses | $122.8M | $167.0M | $164.5M |
| Loss from operations | -$122.8M | -$167.0M | -$164.5M |
| Gain on sale of zaltenibart | $237.6M | $0 | $0 |
| Interest and other income | $4.1M | $11.3M | $16.3M |
| Interest expense, net of remeasurement adjustments and other | $960.0K | -$24.7M | -$30.8M |
| Gain (loss) on change in fair value of financial instruments, net | -$136.7M | $19.0K | $0 |
| Loss from continuing operations before income tax expense | -$2.8M | -$180.3M | -$174.9M |
| Income tax expense | -$2.0M | -$2.3M | $0 |
| Net loss from continuing operations, net of tax | -$4.8M | -$182.6M | -$174.9M |
| Net income from discontinued operations, net of tax | $1.5M | $25.8M | $57.1M |
| Net loss | -$3.4M | -$156.8M | -$117.8M |
| Net loss from continuing operations (in dollars per share) | -$0 | -$3 | -$3 |
| Net loss from continuing operations (in dollars per share) | -$0 | -$3 | -$3 |
| Net income from discontinued operations (in dollars per share) | $0 | $0 | $1 |
| Net income from discontinued operations (in dollars per share) | $0 | $0 | $1 |
| Net loss (in dollars per share) | -$0.05 | -$2.70 | -$1.88 |
| Net loss (in dollars per share) | -$0.05 | -$2.70 | -$1.88 |
| Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares) | 63.5M shares | 58.2M shares | 62.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $9.7M | $3.4M | ||
| Short-term investments | $162.1M | $86.7M | ||
| OMIDRIA contract royalty asset | $25.4M | $29.1M | ||
| Receivables | $10.9M | $7.7M | ||
| Prepaid expense and other assets | $7.6M | $7.2M | ||
| Total current assets | $215.7M | $134.1M | ||
| OMIDRIA contract royalty asset, non-current | $96.4M | $124.3M | ||
| Right of use assets | $10.7M | $15.0M | ||
| Property and equipment, net | $1.8M | $2.7M | ||
| Restricted investments | $1.1M | $1.1M | ||
| Total assets | $325.6M | $277.1M | ||
| Accounts payable | $4.8M | $5.9M | ||
| Accrued expenses | $29.4M | $26.0M | ||
| OMIDRIA royalty obligation | $20.5M | $20.6M | ||
| 2026 Notes, net | $17.1M | $0 | ||
| Term debt | $0 | $21.0M | ||
| Lease liabilities | $6.3M | $6.0M | ||
| Total current liabilities | $78.1M | $79.5M | ||
| OMIDRIA royalty obligation, non-current | $147.3M | $195.6M | ||
| 2026 and 2029 Notes, non-current, net | $51.4M | $97.2M | ||
| Term debt, non-current, net | $0 | $69.6M | ||
| Lease liabilities, non-current | $7.2M | $13.5M | ||
| Other accrued liabilities, non-current | $5.7M | $4.5M | ||
| Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, par value $0.01 per share, 150,000,000 shares authorized at December 31, 2025 and December 31, 2024; 71,670,791 and 58,044,465 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | $716.0K | $580.0K | ||
| Additional paid-in capital | $791.7M | $727.2M | ||
| Accumulated deficit | -$913.7M | -$910.3M | ||
| Total shareholders equity (deficit) | -$121.2M | -$182.6M | -$25.0M | $85.7M |
| Total liabilities and shareholders equity (deficit) | $325.6M | $277.1M | ||
| Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred Stock, Shares Outstanding (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, Shares Issued (in shares) | 0 shares | 0 shares | ||
| Common Stock, Par or Stated Value Per Share (in dollars per share) | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common Stock, Shares, Issued (in shares) | 71.7M shares | 58.0M shares | ||
| Common Stock, Shares, Outstanding (in shares) | 71.7M shares | 58.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $9.7M | $3.4M | ||
| Short-term investments | $162.1M | $86.7M | ||
| OMIDRIA contract royalty asset | $25.4M | $29.1M | ||
| Receivables | $10.9M | $7.7M | ||
| Prepaid expense and other assets | $7.6M | $7.2M | ||
| Total current assets | $215.7M | $134.1M | ||
| OMIDRIA contract royalty asset, non-current | $96.4M | $124.3M | ||
| Right of use assets | $10.7M | $15.0M | ||
| Property and equipment, net | $1.8M | $2.7M | ||
| Restricted investments | $1.1M | $1.1M | ||
| Total assets | $325.6M | $277.1M | ||
| Accounts payable | $4.8M | $5.9M | ||
| Accrued expenses | $29.4M | $26.0M | ||
| OMIDRIA royalty obligation | $20.5M | $20.6M | ||
| 2026 Notes, net | $17.1M | $0 | ||
| Term debt | $0 | $21.0M | ||
| Lease liabilities | $6.3M | $6.0M | ||
| Total current liabilities | $78.1M | $79.5M | ||
| OMIDRIA royalty obligation, non-current | $147.3M | $195.6M | ||
| 2026 and 2029 Notes, non-current, net | $51.4M | $97.2M | ||
| Term debt, non-current, net | $0 | $69.6M | ||
| Lease liabilities, non-current | $7.2M | $13.5M | ||
| Other accrued liabilities, non-current | $5.7M | $4.5M | ||
| Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, par value $0.01 per share, 150,000,000 shares authorized at December 31, 2025 and December 31, 2024; 71,670,791 and 58,044,465 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | $716.0K | $580.0K | ||
| Additional paid-in capital | $791.7M | $727.2M | ||
| Accumulated deficit | -$913.7M | -$910.3M | ||
| Total shareholders equity (deficit) | -$121.2M | -$182.6M | -$25.0M | $85.7M |
| Total liabilities and shareholders equity (deficit) | $325.6M | $277.1M | ||
| Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred Stock, Shares Outstanding (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, Shares Issued (in shares) | 0 shares | 0 shares | ||
| Common Stock, Par or Stated Value Per Share (in dollars per share) | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common Stock, Shares, Issued (in shares) | 71.7M shares | 58.0M shares | ||
| Common Stock, Shares, Outstanding (in shares) | 71.7M shares | 58.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$3.4M | -$156.8M | -$117.8M |
| Gain on sale of zaltenibart | -$237.6M | $0 | $0 |
| Remeasurement on fair value of financial instruments | $136.7M | -$19.0K | $0 |
| Stock-based compensation expense | $8.2M | $10.5M | $11.7M |
| Depreciation and amortization | $964.0K | $950.0K | $920.0K |
| Non-cash interest remeasurement on the OMIDRIA royalty obligation | -$33.4M | -$5.6M | $0 |
| Non-cash interest on OMIDRIA contract royalty asset | -$14.7M | -$16.9M | -$15.3M |
| Remeasurement on OMIDRIA contract royalty asset | $12.7M | -$8.0M | -$41.2M |
| Accretion on U.S. government treasury bills, net | $0 | -$4.4M | -$8.7M |
| OMIDRIA contract royalty asset | $33.6M | $39.7M | $40.6M |
| Accounts payable and accrued expense | $4.6M | -$5.2M | $4.7M |
| Receivables | -$3.2M | $357.0K | $205.1M |
| Prepaid expenses and other | -$1.3M | $517.0K | -$3.0M |
| Net cash provided by (used in) operating activities | -$116.1M | -$148.8M | $74.7M |
| Gross cash proceeds from sale of zaltenibart | $240.0M | $0 | $0 |
| Proceeds from the sale and maturities of investments | $109.9M | $1.1B | $1.0B |
| Purchases of investments | -$185.3M | -$987.4M | -$1.0B |
| Purchases of property and equipment | -$65.0K | -$165.0K | -$426.0K |
| Net cash provided by investing activities | $164.5M | $82.2M | $27.5M |
| Proceeds upon exercise of stock options | $7.7M | $547.0K | $150.0K |
| Repayment of term debt principal | -$67.1M | $0 | $0 |
| Principal payments on OMIDRIA royalty obligation | -$15.0M | -$18.8M | -$1.2M |
| Payments on finance lease obligations | -$749.0K | -$829.0K | -$555.0K |
| Proceeds from sale of future royalties | $0 | $115.5M | $0 |
| Payment on maturity of 2023 Notes | $0 | $0 | -$95.0M |
| Cash paid to repurchase 2026 Notes | $0 | -$21.7M | -$4.9M |
| Repurchases of common stock | $0 | -$11.9M | -$4.7M |
| Net cash provided by (used in) financing activities | -$42.2M | $62.9M | -$106.1M |
| Net increase (decrease) in cash and cash equivalents | $6.3M | -$3.7M | -$3.9M |
| Cash paid for interest | $35.4M | $35.7M | $29.9M |
| Cash paid for income taxes, net | $153.0K | $165.0K | $3.3M |
| Equipment acquired under finance lease | $0 | $1.5M | $952.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led OMEROS CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
2010201520202025
- Chief executive officerGregory A. Demopulos Md. Apr 9, 2010 to now12
- ChairGregory A. Demopulos Md. Apr 9, 2010 to now12
- PresidentGregory A. Demopulos Md. Apr 9, 2010 to now12
Board members and other officers (18)
- VP, Finance & CAODavid J. Borges Jul 3, 2024 to now13
- OfficerPeter B. Cancelmo Jun 11, 2019 to Jul 6, 202114
- VP, Finance and CAO, TreasurerMichael A. Jacobsen Oct 22, 2013 to Apr 29, 202415
- See General RemarksGregory A. Demopulos Md. Oct 7, 2009 to Oct 7, 200916
- VP, Patent & Gen Cnsl, Sec.Marcia S. Kelbon Oct 7, 2009 to Oct 7, 200917
- Board memberJoseph L. Schocken Aug 18, 2026 to now18
- Board memberDiana T. Perkinson May 16, 2023 to now19
- Board memberKurt Zumwalt Feb 12, 2020 to Sep 23, 202220
- Board memberThomas F. Bumol Feb 12, 2019 to now21
- Board memberArnold C. Hanish Sep 28, 2012 to now22
- Board memberGregory A. Demopulos Md. Oct 7, 2009 to Mar 3, 202016
- Board memberJean-Philippe Tripet Oct 7, 2009 to May 31, 201123
- Board memberPeter A. Demopulos Md. Oct 7, 2009 to now24
- Board memberRay Aspiri Oct 7, 2009 to Feb 14, 202225
- Board memberThomas J. Cable Oct 7, 2009 to now26
- Board memberDaniel K. Spiegelman Dec 9, 2009 to Jun 4, 201227
- General counselPeter B. Cancelmo Sep 23, 2022 to now28
- General counselMarcia S. Kelbon Mar 31, 2010 to Jun 11, 201929
Timeline
Filings
213 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 49 major events, 85 insider forms, 19 large holders, 38 other. The latest 20:
- Sep 24, 20264 EDGAR
- Sep 23, 2026144 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 1, 20264 EDGAR
- Aug 31, 2026144 EDGAR
- Aug 28, 2026144 EDGAR
- Aug 28, 20264 EDGAR
- Aug 27, 2026144 EDGAR
- Aug 26, 2026144 EDGAR
- Aug 25, 20264 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 21, 20264 EDGAR
- Aug 20, 2026144 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20263 EDGAR
- Aug 17, 20264 EDGAR
- Aug 13, 2026144 EDGAR
- Aug 13, 2026S-8 EDGAR
- Aug 13, 20268-K EDGAR
- Aug 12, 202610-Q EDGAR
The 213 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
17 open-market trades by officers, directors and large owners since October 2021: 2 buys and 15 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Borges David J.VP, Finance & CAO | Sale | 10,000 | $20.95 | $209.5K | Form 4 |
| Sep 22, 2026 | Borges David J.VP, Finance & CAO | Sale | 10,000 | $20.95 | $209.5K | Form 4 |
| Aug 31, 2026 | Cancelmo Peter BVP, General Counsel | Sale | 25,000 | $18.54 | $463.5K | Form 4 |
| Aug 28, 2026 | Cancelmo Peter BVP, General Counsel | Sale | 25,000 | $18.65 | $466.2K | Form 4 |
| Aug 27, 2026 | HANISH ARNOLD CDirector | Sale | 10,000 | $18.95 | $189.5K | Form 4 |
| Aug 26, 2026 | HANISH ARNOLD CDirector | Sale | 5,000 | $18.53 | $92.7K | Form 4 |
| Aug 24, 2026 | Borges David J.VP, Finance & CAO | Sale | 906 | $19.10 | $17.3K | Form 4 |
| Aug 21, 2026 | Borges David J.VP, Finance & CAO | Sale | 10,000 | $18.95 | $189.5K | Form 4 |
| Aug 20, 2026 | Cable Thomas J.Director | Sale | 15,000 | $18.45 | $276.8K | Form 4 |
| Aug 13, 2026 | Borges David J.VP, Finance & CAO | Sale | 5,000 | $16.95 | $84.8K | Form 4 |
| May 22, 2026 | Cable Thomas J.Director | Sale | 7,500 | $11.61 | $87.1K | Form 4 |
| Jan 13, 2026 | Borges David J.VP, Finance & CAO | Sale | 30,000 | $12.31 | $369.3K | Form 4 |
| Jan 12, 2026 | Borges David J.VP, Finance & CAO | Sale | 30,000 | $12.72 | $381.6K | Form 4 |
| Nov 17, 2023 | Demopulos Gregory A MDChairman, CEO & President | Buy | 15,000 | $1.68 | $25.2K | Form 4 |
| Nov 15, 2023 | Demopulos Peter A MDDirector | Buy | 10,000 | $1.53 | $15.3K | Form 4 |
| May 22, 2023 | HANISH ARNOLD CDirector | Sale | 5,000 | $6.46 | $32.3K | Form 4 |
| May 22, 2023 | Cable Thomas J.Director | Sale | 5,000 | $6.53 | $32.6K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 1 filing Jul 29, 202630
- INGALLS & SNYDER LLCSCHEDULE 13G/A, 5 filings Feb 4, 2022 to Apr 23, 202631
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202632
- Gregory A. Demopulos Md.SC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202433
- Cormorant Asset Management, LPSC 13G/A, 1 filing Feb 14, 202234
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAROMEROS CORP filings on SEC EDGAR
- 2
- 3SEC EDGAROMEROS CORP filings on SEC EDGAR
- 4
- 5SEC EDGAROMEROS CORP 10-K for fiscal 2020
- 6SEC EDGAROMEROS CORP 10-K for fiscal 2020
- 7SEC EDGAROMEROS CORP 10-K for fiscal 2019
- 8SEC EDGAROMEROS CORP 10-Q for fiscal 2026
- 9SEC EDGAROMEROS CORP 10-Q for fiscal 2026
- 10
- 11SEC EDGAROMEROS CORP 10-K for fiscal 2020
- 12
- 13SEC EDGARDavid J. Borges, VP, Finance & CAO
- 14SEC EDGARPeter B. Cancelmo, Officer
- 15
- 16
- 17
- 18SEC EDGARJoseph L. Schocken, Board member
- 19SEC EDGARDiana T. Perkinson, Board member
- 20SEC EDGARKurt Zumwalt, Board member
- 21SEC EDGARThomas F. Bumol, Board member
- 22SEC EDGARArnold C. Hanish, Board member
- 23SEC EDGARJean-Philippe Tripet, Board member
- 24SEC EDGARPeter A. Demopulos Md., Board member
- 25SEC EDGARRay Aspiri, Board member
- 26SEC EDGARThomas J. Cable, Board member
- 27SEC EDGARDaniel K. Spiegelman, Board member
- 28SEC EDGARPeter B. Cancelmo, General counsel
- 29SEC EDGARMarcia S. Kelbon, General counsel
- 30
- 31
- 32
- 33
- 34